Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew McGarry

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Journal of Huntington'S Disease|November 9, 2020
Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD StudyAndrew McGarry, Mika Leinonen, Karl Kieburtz, et al.
Brain Sciences|December 24, 2025
Alpha-Synuclein Neurobiology in Parkinson's Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic PerspectivesJamir Pitton Rissardo, Andrew McGarry, Yiwen Shi, et al.
Brain Sciences|July 29, 2025
Neurobiology of Dystonia: Review of Genetics, Animal Models, and NeuroimagingJamir Pitton Rissardo, Andrew McGarry, Yiwen Shi, et al.
Neurology. Clinical Practice|June 24, 2022
Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington DiseaseAndrew McGarry, Peggy Auinger, Karl D Kieburtz, et al.
Journal of Huntington'S Disease|August 23, 2017
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's DiseaseAndrew McGarry, Karl Kieburtz, Victor Abler, et al.
Plos Currents|May 3, 2011
Advocacy Recruiting for Huntington's Disease Clinical TrialsLavonne Goodman, Cherrie Sia, Roger Carnes, et al.
Scientific Reports|January 11, 2024
An exploratory metabolomic comparison of participants with fast or absent functional progression from 2CARE, a randomized, double-blind clinical trial in Huntington's diseaseAndrew McGarry, Krystal Hunter, John Gaughan, et al.
Neurology|March 10, 2019
Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trialAndrew McGarry, Michael P McDermott, Karl Kieburtz, et al.
Scientific Reports|November 25, 2020
Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot studyAndrew McGarry, John Gaughan, Cory Hackmyer, et al.
Scientific Reports|May 6, 2021
Author Correction: Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot studyAndrew McGarry, John Gaughan, Cory Hackmyer, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Journal of Huntington'S Disease|November 9, 2020
Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD StudyAndrew McGarry, Mika Leinonen, Karl Kieburtz, et al.
Brain Sciences|December 24, 2025
Alpha-Synuclein Neurobiology in Parkinson's Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic PerspectivesJamir Pitton Rissardo, Andrew McGarry, Yiwen Shi, et al.
Brain Sciences|July 29, 2025
Neurobiology of Dystonia: Review of Genetics, Animal Models, and NeuroimagingJamir Pitton Rissardo, Andrew McGarry, Yiwen Shi, et al.
Neurology. Clinical Practice|June 24, 2022
Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington DiseaseAndrew McGarry, Peggy Auinger, Karl D Kieburtz, et al.
Journal of Huntington'S Disease|August 23, 2017
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's DiseaseAndrew McGarry, Karl Kieburtz, Victor Abler, et al.
Plos Currents|May 3, 2011
Advocacy Recruiting for Huntington's Disease Clinical TrialsLavonne Goodman, Cherrie Sia, Roger Carnes, et al.
Scientific Reports|January 11, 2024
An exploratory metabolomic comparison of participants with fast or absent functional progression from 2CARE, a randomized, double-blind clinical trial in Huntington's diseaseAndrew McGarry, Krystal Hunter, John Gaughan, et al.
Neurology|March 10, 2019
Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trialAndrew McGarry, Michael P McDermott, Karl Kieburtz, et al.
Scientific Reports|November 25, 2020
Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot studyAndrew McGarry, John Gaughan, Cory Hackmyer, et al.
Scientific Reports|May 6, 2021
Author Correction: Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot studyAndrew McGarry, John Gaughan, Cory Hackmyer, et al.
Pageof 4